Combination Therapy with Cyclosporine and Psoralen Plus Ultraviolet A in the Patients with Severe Alopecia Areata: A Retrospective Study with a Self-Controlled Design.
- Author:
Kui Young PARK
1
;
Woo Sun JANG
;
In Pyeong SON
;
Sun Young CHOI
;
Moo Yeol LEE
;
Beom Joon KIM
;
Myeung Nam KIM
;
Byung In RO
Author Information
- Publication Type:Original Article
- Keywords: Alopecia areata; Cyclosporine; PUVA therapy; Side effect
- MeSH: Adult; Alopecia; Alopecia Areata; Autoimmune Diseases; Child; Cyclosporine; Ficusin; Hair Follicle; Humans; Lost to Follow-Up; PUVA Therapy; Retrospective Studies
- From:Annals of Dermatology 2013;25(1):12-16
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Alopecia areata (AA) is believed to be an organ-specific autoimmune disease in which a mononuclear cell infiltrate develops in and around anagen hair follicles. There is no definitive therapy for AA. OBJECTIVE: We sought to determine whether the combination therapy of cyclosporine and psoralen plus ultraviolet A (PUVA) could be an effective treatment for severe AA. METHODS: A total of 41 patients with severe AA were treated with oral cyclosporine and topical PUVA. Cyclosporine was given at an initial daily dose of 200 mg for adult and 100 mg for children for periods of up to 16 weeks. Eight-methoxypsoralen (Methoxsalen) was applied topically 20 minutes prior to ultraviolet A (UVA) exposure, and the patients were irradiated with UVA twice a week for 16 weeks. RESULTS: Of the total 41 patients, 2 (7.3%) patients were lost to follow-up, and 1 (2.4%) patient discontinued the treatment due to abdominal discomfort. Six (14.6%) patients were treated for less than 12 weeks. Of remaining 32 patients, 3 (9.4%) showed excellent response, 3 (9.4%) showed good response, 12 (37.5%) showed fair response, and 14 (43.7%) showed poor response. CONCLUSION: Although limited by its uncontrolled character, this study shows that the combination therapy with cyclosporine and PUVA may be an additional choice for severe and recalcitrant AA.
